Jason B. Daly
CIK: 0001906486
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Amneal Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Aug 12, 2026AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct210K shares at avg. $17.40$3.7M - Aug 11, 2026AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct6.6K shares at avg. $17.70$117K - Mar 4, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct35.9K shares- - Mar 4, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct15.6K shares at avg. $13.30$207K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct24.3K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct10.5K shares at avg. $13.31$140K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct305.8K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct132.8K shares at avg. $13.31$1.8M - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct22.6K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct10.1K shares at avg. $13.31$135K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct38.2K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct16.6K shares at avg. $13.31$221K - Mar 2, 2026AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectPerformance-Based Restricted Stock Units
65.4K shares- - Mar 2, 2026AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
65.4K shares- - Aug 12, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct22K shares at avg. $9.05$199K - Mar 6, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct46.9K shares at avg. $8.73$410K - Mar 5, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct43.1K shares at avg. $8.88$382K - Mar 4, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct35.9K shares- - Mar 4, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct15.6K shares at avg. $8.84$138K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct10.9K shares at avg. $8.76$95K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct90.6K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct31.3K shares at avg. $8.76$275K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
97K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct22.6K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct6.9K shares at avg. $8.76$61K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 210,000 | $17.40 | $3,654,000 | Direct |
| Aug 11, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 6,613 | $17.70 | $117,050 | Direct |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 35,880 | - | $0 | Direct |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 15,580 | $13.30 | $207,214 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 24,258 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 10,533 | $13.31 | $140,194 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 305,810 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 132,783 | $13.31 | $1,767,342 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 22,645 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 10,147 | $13.31 | $135,057 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 38,226 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 16,598 | $13.31 | $220,919 | Direct |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Performance-Based Restricted Stock Units | 65,359 | - | - | Direct |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 65,359 | - | - | Direct |
| Aug 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 22,000 | $9.05 | $199,100 | Direct |
| Mar 6, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 46,936 | $8.73 | $409,751 | Direct |
| Mar 5, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 43,064 | $8.88 | $382,408 | Direct |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 35,879 | - | - | Direct |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 15,579 | $8.84 | $137,718 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 10,864 | $8.76 | $95,169 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 90,580 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 31,338 | $8.76 | $274,521 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 97,032 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 22,645 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 6,943 | $8.76 | $60,821 | Direct |
1-25 of 29 transactions
About Daly Jason B.
Daly Jason B. (SEC CIK 0001906486) files insider reports with the SEC as EVP, Chief Legal Officer of Amneal Pharmaceuticals, Inc. (AMRX).
Signal8 holds 8 ownership filings by Daly Jason B., all Form 4s, filed between Nov 19, 2024 and Aug 13, 2026. Those filings report 29 transactions, from Nov 15, 2024 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Daly Jason B.'s filings is in BRIDGEWATER, NJ.
Recent filings by Daly Jason B.
- Aug 12, 2026: Open-market sale of AMRX shares (Form 4, code S).
- Aug 11, 2026: Open-market sale of AMRX shares (Form 4, code S).
- Mar 4, 2026: Option exercise of AMRX shares (Form 4, code M).
- Mar 4, 2026: Tax withholding of AMRX shares (Form 4, code F).
- Mar 3, 2026: Option exercise of AMRX shares (Form 4, code M).
Other insiders filing for Amneal Pharmaceuticals, Inc. (AMRX)
- BUCHI J KEVIN, Director
- BOYER ANDREW S, Executive Vice President
- Kiely John, Director
- Shah Nikita, Executive Vice President
- Patel Tushar Bhikhubhai, 10% Owner
- Patel Chintu, Co-CEO